TransCode Therapeutics Inc (NASDAQ:RNAZ) announced acceptance for publication by Frontiers in Molecular Biosciences of a preclinical study using TransCode’s lead therapeutic candidate, TTX-MC138, in glioblastoma multiforme (GBM).
The findings of this study support further development of TTX-MC138 for GBM by identifying a potentially successful combination treatment protocol using TTX-MC138 with temozolomide (TMZ), currently the standard-of-care therapeutic.
Treatment of human glioblastoma cells implanted in animals with the TTX-MC138 analog, MN-anti-miR10b, inhibited tumor cell growth and induced cell death.
When combined with a sub-therapeutic dose of TMZ in a sequence-specific protocol, MN-anti-miR10b enhanced the cell-killing ability of TMZ, resulting in highly successful inhibition of tumor cell survival and invasiveness.
The company says that in a preclinical model of pancreatic adenocarcinoma, administration of TTX-MC138 as monotherapy resulted in complete responses, manifested as regression without recurrence, in 40% of treated animals.
This study comes on the heels of preclinical breast cancer studies demonstrating complete metastatic disease regressions.
In addition to murine models of cancer, TTX-MC138 was successfully delivered and demonstrated preliminary efficacy in a case study of spontaneous feline mammary carcinoma.
TransCode also priced its public offering of 2 million shares at $3.50 per share for gross proceeds of $7 million. Each common stock is offered with a Series A-1 warrant to purchase one share at an exercise price of $3.25 per share and a Series A-2 warrant to purchase one share at an exercise price of $3.25 per share.
Price Action: RNAZ shares are up 6.54% at $3.42 during the premarket session on the last check Wednesday.
